Search: WFRF:(Palmer T)
> (2000-2004) >
Design and baseline...
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
-
- Pedersen, T.R. (author)
- Center for Preventive Medicine, Ullevål University Hospital, Oslo, Norway, Center for Preventive Medicine, Building K, Ulleval Univ. Hosp., N-0407 Oslo, N.
-
- Faergeman, O. (author)
- Department of Medicine-Cardiology A, Århus University Hospital, Århus, Denmark
-
- Kastelein, J.J.P. (author)
- Academic Hospital Amsterdam, Amsterdam, The Netherlands
-
show more...
-
- Olsson, Anders (author)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Internmedicin,Endokrin- och magtarmmedicinska kliniken US
-
- Tikkanen, M.J. (author)
- Medical Clinic, Helsinki University Hospital, Helsinki, Finland
-
- Holme, I. (author)
- Center for Preventive Medicine, Ullevål University Hospital, Oslo, Norway
-
- Larsen, M.L. (author)
- Department of Medicine-Cardiology A, Århus University Hospital, Århus, Denmark
-
- Bendiksen, F.S. (author)
- Hamar, Lysaker, Norway
-
- Lindahl, C. (author)
- Pfizer Sweden, Täby, Sweden
-
- Palmer, G. (author)
- Pfizer Inc., New York, New York, USA
-
show less...
-
Center for Preventive Medicine, Ullevål University Hospital, Oslo, Norway, Center for Preventive Medicine, Building K, Ulleval Univ Hosp., N-0407 Oslo, N. Department of Medicine-Cardiology A, Århus University Hospital, Århus, Denmark (creator_code:org_t)
- Elsevier BV, 2004
- 2004
- English.
-
In: American Journal of Cardiology. - : Elsevier BV. - 0002-9149 .- 1879-1913. ; 94:6, s. 720-724
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) study is an investigator-initiated trial designed to determine whether additional clinical benefit might be gained through a strategy that decreases levels of low-density lipoprotein cholesterol levels better than those currently achieved with established statin therapy in patients who have coronary heart disease. IDEAL is a multicenter prospective, randomized, open-label, blinded, end point classification study. Patients who had myocardial infarction were randomized to prescription treatment with 80 mg/day of atorvastatin or 20 mg/day of simvastatin (the dose was increased to 40 mg/day at week 24 in those patients whose plasma total cholesterol remained >5.0 mmol/L, or 190 mg/dl, or whose low-density lipoprotein cholesterol remained >3.0 mmol/L, or 115 mg/dl). The primary clinical outcome variable is the time to initial occurrence of a major coronary event, which is defined as nonfatal acute myocardial infarction, coronary death, or resuscitated cardiac arrest. The study is designed to have a power of 90% to detect a relative decrease of 20% in the atorvastatin-group compared with the simvastatin-group in the number of major events caused by coronary heart disease over ~5.5 years. The 8,888 randomized patients had the following characteristics: mean age 61.7 ± 9.5 years, 19.1% women (mean age 64.0 ± 9.5 years), baseline total cholesterol 5.1 ± 1.0 mmol/L (197 mg/dl), low-density lipoprotein cholesterol 3.2 ± 0.9 mmol/L (124 mg/dl), and high-density lipoprotein cholesterol 1.2 ± 0.3 mmol/L (46 mg/dl). Drug treatment before randomization consisted of statins in 77% of patients, aspirin in 78.9%, ß blockers in 75.1%, and angiotensin-converting enzyme inhibitors in 30%. © 2004 by Excerpta Medica, Inc.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Pedersen, T.R.
-
Faergeman, O.
-
Kastelein, J.J.P ...
-
Olsson, Anders
-
Tikkanen, M.J.
-
Holme, I.
-
show more...
-
Larsen, M.L.
-
Bendiksen, F.S.
-
Lindahl, C.
-
Palmer, G.
-
show less...
- Articles in the publication
-
American Journal ...
- By the university
-
Linköping University